Multiple Myeloma: all 3,712 studies
Page 29 of 38. Open to participants first (752), then studies with results posted, then the rest; newest registration first within each.
- PENELOPE Observational Study: Prophylaxis and Treatment of Arterial and Venous ThromboembolismCompletedNCT01855698
- Oral Bicarbonate as Adjuvant for Pain Reduction in Patients With Tumor Related PainTerminatedNCT01846429Phase 1
- Prospective Research Assessment in Multiple Myeloma: An Observational Evaluation (PREAMBLE)Active, not recruitingNCT01838512
- A Phase II Study of BI-505 in Smoldering Multiple MyelomaTerminatedNCT01838369Phase 2
- A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal InjectionTerminatedNCT01829971Phase 1
- Whole Body Diffusion Weighted Magnetic Resonance Imaging (DW-MRI) in Multiple MyelomaCompletedNCT01829412Not applicable
- Ipilimumab or Nivolumab in Treating Patients With Relapsed Hematologic Malignancies After Donor Stem Cell TransplantCompletedNCT01822509Phase 1
- Cancer Stem Cells in Multiple MyelomaCompletedNCT01820546
- Carfilzomib and Dexamethasone in Treating Patients With Multiple Myeloma Who Previously Underwent a Stem Cell TransplantWithdrawnNCT01812720Phase 2
- Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in ChinaStatus unknownNCT01812096Phase 1/2
- Acupuncture for Symptom Control in Hematopoietic Stem Cell Transplantation PatientsCompletedNCT01811862Not applicable
- Multiple Myeloma and ExerciseCompletedNCT01809717Not applicable
- A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard TherapyCompletedNCT01794507Phase 1
- Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Progressive Multiple MyelomaStatus unknownNCT01792102Phase 1/2
- First Line Treatment Trial in Multiple Myeloma, Finnish Myeloma Group- Multiple Myeloma 02CompletedNCT01790737Phase 2
- Whole Body MRI Imaging in Multiple Myeloma at 3 Tesla MRI : Added Value of Diffusion Weighted ImagingStatus unknownNCT01780766
- SST0001 (Roneparstat) in Advanced Multiple MyelomaCompletedNCT01764880Phase 1
- Dose Escalation Trial of WT1-specific Donor-derived T Cells Following T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed/Refractory Multiple MyelomaCompletedNCT01758328Phase 1
- Bone Marrow and Kidney Transplant for Patients With Chronic Kidney Disease and Blood DisordersCompletedNCT01758042Not applicable
- Study of Hypotensive Hematopoietic Malignancy Patients' USCOM ReadingsCompletedNCT01755000Not applicable
- An Exploratory Safety Study to Investigate the Extent of Tumor Cell Mobilization (TCM) After Use of G-CSF Alone or G-CSF Plus Plerixafor in Multiple Myeloma (MM) Patients Who May be Poor Mobilizers of Stem CellsCompletedNCT01753453Phase 2
- A Non-interventional, Observational Post-marketing Registry of Patients Treated With Revlimid (Lenalidomide) in TaiwanCompletedNCT01752075
- Lenalidomide After Allo TransplantTerminatedNCT01750762Phase 1
- SAR650984 (Isatuximab), Lenalidomide, and Dexamethasone in Combination in RRMM PatientsCompletedNCT01749969Phase 1
- Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingNCT01746849Phase 2
- Geriatric Assessments in Senior Adults With Multiple MyelomaCompletedNCT01746030
- Pomalidomide and Dexamethasone Effects in Multiple Myeloma Patients With Del 17p or t (4;14)CompletedNCT01745640Phase 2
- An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)TerminatedNCT01742793Phase 1
- First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDDTerminatedNCT01728259Phase 1
- Safety and Preliminary Efficacy Study of the Antibody PAT-SM6 in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01727778Phase 1
- A Phase 1 Study Evaluating AMG 232 in Advanced Solid Tumors or Multiple MyelomaCompletedNCT01723020Phase 1
- Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)CompletedNCT01720875Phase 2
- Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple MyelomaCompletedNCT01718899Phase 1
- Safety Study of Anti LewisY Chimeric Antigen Receptor in Myeloma, Acute Myeloid Leukemia or Myelodysplastic SyndromeStatus unknownNCT01716364Phase 1
- A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01711671Phase 1
- Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT01711528Phase 1
- Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide MaintenanceCompletedNCT01702831Phase 2
- Bendamustine, Lenalidomide (Revlimid®) and Dexamethasone (BRd) as 2nd-line Therapy for Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01701076Phase 2
- Assessment of Impact Nutritional Program During Autologous Stem Cell TransplantTerminatedNCT01699581Phase 2
- Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma PatientsCompletedNCT01697839
- Safety, Efficacy and Pharmacokinetic Study of PRLX 93936 in Patients With Multiple MyelomaStatus unknownNCT01695590Phase 1/2
- C11-Acetate PET/CT in Multiple Myeloma: Added Value to F18-Fluorodeoxyglucose PET/CTCompletedNCT01691300Not applicable
- Hydroxychloroquine, Cyclophosphamide, Dexamethasone, and Sirolimus in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01689987Phase 1
- Study of Bendamustine, Lenalidomide and Low-dose Dexamethasone, for the Treatment of Patients With Relapsed MyelomaStatus unknownNCT01686386Phase 1/2
- Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide MaintenanceStatus unknownNCT01685814Phase 3
- Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple MyelomaWithdrawnNCT01680796Phase 1
- An Observational Study of Chinese Multiple Myeloma Patients Treated With VelcadeCompletedNCT01675245
- Autologous Stem Cell Transplantation for Myeloma Patients Over 65 YearsStatus unknownNCT01671826
- Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01665794Phase 1/2
- Total Marrow Irradiation and High-dose Melphalan for Double Autologous Hematopoietic Stem Cell Transplantation in Multiple MyelomaStatus unknownNCT01665014Phase 2
- Phase I Study of Milatuzumab for Graft Versus Host DiseaseTerminatedNCT01663766Phase 1
- MLN9708 and Dexamethasone for High-Risk Smoldering Multiple MyelomaWithdrawnNCT01660997Phase 2
- A Safety Study of Carfilzomib, Cyclophosphamide & Dexamethasone Prior to ASCT in Patients With Newly Diagnosed MyelomaCompletedNCT01660750Phase 1
- Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous TransplantationCompletedNCT01660633Phase 2
- Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic MalignanciesCompletedNCT01658319Phase 1
- Panobinostat Biological Correlates StudyCompletedNCT01658241Phase 2
- Randomized Trial of Cryotherapy Duration Prior to High Dose Melphalan in Myeloma PatientsCompletedNCT01653106Not applicable
- Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic MalignanciesWithdrawnNCT01652014Phase 2
- Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib MaintenanceWithdrawnNCT01647165Phase 2
- Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic MalignanciesTerminatedNCT01643603Phase 1
- BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple MyelomaCompletedNCT01638936Phase 1/2
- Inducible Regulatory T Cells (iTregs) in Non-Myeloablative Sibling Donor Peripheral Blood Stem Cell TransplantationCompletedNCT01634217Phase 1
- Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple MyelomaApproved for marketingNCT01632826
- Biosimilar Retacrit™ (Epoetin Zeta) in the Treatment of Chemotherapy-Induced Symptomatic Anaemia in Haematology and OncologyCompletedNCT01626547
- Engraftment Syndrome After Autologous Stem Cell Transplant: Retrospective Review in Patients With Multiple MyelomaCompletedNCT01622582
- NK Cells in Cord Blood TransplantationStatus unknownNCT01619761Phase 1
- Genomic-Based Diagnosis, Classification and Targeted Treatment of Multiple MyelomaStatus unknownNCT01619358
- Autologous Stem Cell Transplantation and Maintenance Therapy for Multiple MyelomaTerminatedNCT01617213Phase 2
- Pilot Study of Lymphoid Tumor Microenvironmental Dysruption Prior to Autologous Stem Cell TransplantationTerminatedNCT01610999Phase 1
- Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgkin, or Hodgkin LymphomaTerminatedNCT01609816Phase 1
- Autophagy Induction After Bortezomib for MyelomaCompletedNCT01594242Early Phase 1
- Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple MyelomaCompletedNCT01593410Phase 2
- Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell TransplantCompletedNCT01588015Phase 1
- Study of ACY-1215 in Combination With Lenalidomide, and Dexamethasone in Multiple MyelomaCompletedNCT01583283Phase 1
- XL184 For Relapsed/Refractory Multiple Myeloma (MM) With Bone DiseaseCompletedNCT01582295Phase 1
- Safety and Pharmacokinetic Profile of CKD-581CompletedNCT01580371Phase 1
- Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)CompletedNCT01575925Phase 1
- Urinary Protein/Creatinine Ratio in a Single Urine Sample Versus 24-hour Proteinuria in Patients With Multiple MyelomaCompletedNCT01572857
- Safety and Efficacy Study of High Dose Melphalan to Treat Multiple MyelomaStatus unknownNCT01572688Not applicable
- Imaging Studies and the Development of Multiple MyelomaWithdrawnNCT01571726Phase 2
- Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple MyelomaCompletedNCT01568294Phase 1
- Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple MyelomaActive, not recruitingNCT01562405Phase 1
- Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell TransplantWithdrawnNCT01558778Not applicable
- Telomerase Activity as a Marker For Mobilization QualityStatus unknownNCT01555359
- Nelfinavir and Lenalidomide/Dexamethasone in Progressive Multiple MyelomaTerminatedNCT01555281Phase 1/2
- Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma PatientsStatus unknownNCT01554852Phase 3
- Study of the Combination of Panobinostat & Carfilzomib in Patients With Relapsed &/or Refractory Multiple MyelomaCompletedNCT01549431Phase 1
- Pomalidomide, Dexamethasone and Pegylated Liposomal Doxorubicin for Relapsed/Refractory Multiple MyelomaStatus unknownNCT01541332Phase 1/2
- Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple MyelomaTerminatedNCT01537861Early Phase 1
- Viral Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT01533194Phase 1
- Iberoamerican Protocol With Thalidomide in Patients With Symptomatic Newly Diagnosed Multiple Myeloma Over 65 YearsStatus unknownNCT01532856Phase 3
- Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple MyelomaCompletedNCT01530594Phase 3
- Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MMCompletedNCT01526694Phase 2
- Retrospective Survey of Re-treatment With BortezomibCompletedNCT01524445
- Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple MyelomaStatus unknownNCT01522872Phase 1/2
- NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple MyelomaCompletedNCT01521533Phase 2
- Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple MyelomaTerminatedNCT01518465Phase 2
- Bortezomib Consolidation TrialCompletedNCT01517724Phase 2
- Study of Thrombin Generation During the 3 First Cycles of Chemotherapy in Patients With Newly Diagnosed Multiple MyelomaCompletedNCT01508416
- Phase I Study of CS-7017 and BexaroteneTerminatedNCT01504490Phase 1